The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...

The antibiotic, branded as Blujepa, is approved for women aged 12 years and older to treat uncomplicated UTIs, which are ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat uncomplicated urinary tract infections (uUTIs). The drug, which is the first in a ...

London: GSK plc has announced that the Company has received US Food and Drug Administration (FDA) approval for Blujepa ...

Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract ...